<DOC>
	<DOCNO>NCT01673386</DOCNO>
	<brief_summary>This randomize , double-blind , 2-arm crossover study compare tivozanib hydrochloride sunitinib subject metastatic RCC receive prior systemic therapy Renal Cell Carcinoma ( RCC ) . Approximately 160 subject stratify ECOG score ( 0 vs 1 ) histology ( clear cell v non-clear cell ) randomize 1:1 1 2 treatment arm . The study consist two 12-week treatment period 1-week washout . Subjects receive double-blind ( over-encapsulated ) tivozanib hydrochloride sunitinib sequentially . The study design compare subject treatment preference , well overall safety tolerability , frequency dose modification kidney-specific health outcomes/QoL .</brief_summary>
	<brief_title>A Subject Treatment Preference Study Tivozanib Hydrochloride Versus Sunitinib Subjects With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Unresectable mRCC Histologically cytologically confirm RCC histology Subjects without prior nephrectomy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Any prior systemic therapy treatment mRCC ( include investigational license drug target VEGF VEGF receptors/pathway , mammalian target rapamycin [ mTOR ] inhibitor ) Central nervous system malignancy metastases Significant hematologic , gastrointestinal , thromboembolic , vascular , bleeding , coagulation disorder Significant serum chemistry urinalysis abnormality Significant cardiovascular disease , include symptomatic leave ventricular ejection fraction baseline LVEF â‰¤ institutional low limit normal , uncontrolled hypertension , myocardial infarction severe angina within 6 month prior administration first dose study drug , history class III IV congestive heart failure , history serious ventricular arrhythmia , cardiac arrhythmia , coronary peripheral bypass graft within 6 month screen Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula Currently active second primary malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Tivozanib hydrochloride</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>subject preference</keyword>
	<keyword>quality life</keyword>
</DOC>